Stifel Financial Corp Sells 17,540 Shares of The Chemours Company (NYSE:CC)

Stifel Financial Corp lessened its position in shares of The Chemours Company (NYSE:CC) by 50.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,146 shares of the specialty chemicals company’s stock after selling 17,540 shares during the period. Stifel Financial Corp’s holdings in Chemours were worth $348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Matrix Trust Co acquired a new position in shares of Chemours during the 3rd quarter worth approximately $25,000. Blue Trust Inc. grew its position in Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 731 shares in the last quarter. Truvestments Capital LLC bought a new position in Chemours during the 3rd quarter worth $35,000. Brooklyn Investment Group acquired a new position in Chemours in the 3rd quarter valued at $37,000. Finally, Signaturefd LLC raised its holdings in Chemours by 163.7% in the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after acquiring an additional 1,216 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is owned by insiders.

Chemours Stock Down 1.8 %

Shares of NYSE CC opened at $17.01 on Friday. The Chemours Company has a 1 year low of $15.10 and a 1 year high of $32.70. The stock has a market capitalization of $2.54 billion, a P/E ratio of 34.02 and a beta of 1.80. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The company has a 50-day moving average price of $19.49 and a 200-day moving average price of $20.36.

Chemours (NYSE:CC) last announced its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter in the prior year, the company posted $0.64 earnings per share. Chemours’s revenue was up .9% compared to the same quarter last year. On average, equities research analysts forecast that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.88%. The ex-dividend date of this dividend was Friday, November 15th. Chemours’s dividend payout ratio is presently 200.00%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. BMO Capital Markets raised their target price on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. The Goldman Sachs Group dropped their target price on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a report on Tuesday, September 3rd. Morgan Stanley reduced their price target on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. Finally, Barclays upped their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.88.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.